These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31581156)

  • 1. Note: Zolgensma data manipulation.
    Med Lett Drugs Ther; 2019 Aug; 61(1579):129. PubMed ID: 31581156
    [No Abstract]   [Full Text] [Related]  

  • 2. Zolgensma - one-time gene therapy for spinal muscular atrophy.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):113-114. PubMed ID: 31381549
    [No Abstract]   [Full Text] [Related]  

  • 3. Onasemnogene Abeparvovec: First Global Approval.
    Hoy SM
    Drugs; 2019 Jul; 79(11):1255-1262. PubMed ID: 31270752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
    Dean R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Wiesner T; Malone DC; Bischof M; Toro W; Dabbous O
    J Mark Access Health Policy; 2021 Feb; 9(1):1889841. PubMed ID: 33708361
    [No Abstract]   [Full Text] [Related]  

  • 5. In brief: Risdiplam (Evrysdi) for spinal muscular atrophy.
    Med Lett Drugs Ther; 2021 Jul; 63(1629):e1-e2. PubMed ID: 34544108
    [No Abstract]   [Full Text] [Related]  

  • 6. Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy.
    Schwartz M; Likhite S; Meyer K
    Drugs Today (Barc); 2021 Jun; 57(6):387-399. PubMed ID: 34151905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy.
    Stevens D; Claborn MK; Gildon BL; Kessler TL; Walker C
    Ann Pharmacother; 2020 Oct; 54(10):1001-1009. PubMed ID: 32204605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1.
    Al-Zaidy SA; Mendell JR
    Pediatr Neurol; 2019 Nov; 100():3-11. PubMed ID: 31371124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs.
    Ballreich J; Ezebilo I; Khalifa BA; Choe J; Anderson G
    J Manag Care Spec Pharm; 2022 Jan; 28(1):39-47. PubMed ID: 34949120
    [No Abstract]   [Full Text] [Related]  

  • 10. Modern approaches in gene therapy of motor neuron diseases.
    Zakharova M
    Med Res Rev; 2021 Sep; 41(5):2634-2655. PubMed ID: 32638429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy.
    Kirschner J; Butoianu N; Goemans N; Haberlova J; Kostera-Pruszczyk A; Mercuri E; van der Pol WL; Quijano-Roy S; Sejersen T; Tizzano EF; Ziegler A; Servais L; Muntoni F
    Eur J Paediatr Neurol; 2020 Sep; 28():38-43. PubMed ID: 32763124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent 'value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective.
    Connock M; Andronis L; Auguste P; Dussart C; Armoiry X
    Expert Opin Biol Ther; 2020 Jul; 20(7):823-827. PubMed ID: 32434404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
    Bitetti I; Lanzara V; Margiotta G; Varone A
    Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recommendations for gene therapy of spinal muscular atrophy with onasemnogene abeparvovec-AVXS-101 : Consensus paper of the German representatives of the Society for Pediatric Neurology (GNP) and the German treatment centers with collaboration of the medical scientific advisory board of the German Society for Muscular Diseases (DGM)].
    Ziegler A; Wilichowski E; Schara U; Hahn A; Müller-Felber W; Johannsen J; von der Hagen M; von Moers A; Stoltenburg C; Saffari A; Walter MC; Husain RA; Pechmann A; Köhler C; Horber V; Schwartz O; Kirschner J
    Nervenarzt; 2020 Jun; 91(6):518-529. PubMed ID: 32394004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series.
    Chand DH; Zaidman C; Arya K; Millner R; Farrar MA; Mackie FE; Goedeker NL; Dharnidharka VR; Dandamudi R; Reyna SP
    J Pediatr; 2021 Apr; 231():265-268. PubMed ID: 33259859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
    Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
    Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The White Coat Cape: An Ethical Analysis of Emerging Therapies to Treat Spinal Muscular Atrophy.
    Hartsock JA
    Semin Pediatr Neurol; 2023 Apr; 45():101036. PubMed ID: 37003633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations.
    Simoens S; Huys I
    Gene Ther; 2017 Sep; 24(9):539-541. PubMed ID: 28880019
    [No Abstract]   [Full Text] [Related]  

  • 19. Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy.
    Burgart AM; Magnus D; Tabor HK; Paquette ED; Frader J; Glover JJ; Jackson BM; Harrison CH; Urion DK; Graham RJ; Brandsema JF; Feudtner C
    JAMA Pediatr; 2018 Feb; 172(2):188-192. PubMed ID: 29228163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience.
    Friese J; Geitmann S; Holzwarth D; Müller N; Sassen R; Baur U; Adler K; Kirschner J
    J Neuromuscul Dis; 2021; 8(2):209-216. PubMed ID: 33427694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.